Point72 Hong Kong LTD Atara Biotherapeutics, Inc. Transaction History

Point72 Hong Kong LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $18,302 - $56,064	6,422 New	6,422 $24,000
Q2 2022 Aug 15, 2022	SELL	$4.69 - $9.84 $33,927 - $71,182	-7,234 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $47,297 - $94,651	5,604 Added 343.8%	7,234 $67,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $91,360 - $123,616	-6,215 Reduced 79.22%	1,630 $26,000
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $86,567 - $129,237	7,220 Added 1155.2%	7,845 $140,000
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $14,114 - $18,155	-1,095 Reduced 63.66%	625 $10,000
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $19,236 - $28,469	-1,374 Reduced 44.41%	1,720 $25,000
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $39,200 - $81,155	3,094 New	3,094 $61,000
Q3 2020 Nov 16, 2020	SELL	$11.92 - $15.87 $63,605 - $84,682	-5,336 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $40,180 - $79,666	5,336 New	5,336 $78,000
Q3 2019 Nov 14, 2019	SELL	$12.03 - $19.94 $8,866 - $14,695	-737 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $14,039 - $30,246	737 New	737 $15,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.